Clinical trial
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With…
NCT00323791 · University of Medicine and Dentistry of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00323791 |
|---|---|
| Title | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug, Genetic, Other |
| Interventions | gemcitabine hydrochloride, imatinib mesylate, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis |
| Enrollment | 100 |
| Start date | Apr 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | May 10, 2006 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: